Niemann-Pick Disease Type A/B
An inherited disorder caused by acid sphingomyelinase deficiency, ranging from a severe infantile neurodegenerative form (Type A) to a milder, primarily visceral form (Type B).
- Caused by SMPD1 gene mutations
- Acid sphingomyelinase deficiency
- Autosomal recessive inheritance
- Enzyme replacement therapy available for Type B
- Disease Group
- Lysosomal Storage Disorders
- Inheritance Pattern
- Autosomal Recessive (SMPD1 gene)
- Onset Range
- Infancy (Type A) to Childhood/Adulthood (Type B)
- Advanced Therapies
- Enzyme Replacement Therapy (Type B), Research into CNS-targeted approaches
Condition Overview
Niemann-Pick Disease Type A and Type B are caused by deficiency of the enzyme acid sphingomyelinase (ASM), which is needed to break down a fatty substance called sphingomyelin. When ASM activity is deficient, sphingomyelin accumulates within cells of the liver, spleen, lungs, and in Type A, the brain.
Type A is a severe, rapidly progressive neurodegenerative disorder presenting in infancy, with profound developmental regression and a markedly shortened lifespan. Type B is generally milder and primarily involves the liver, spleen, and lungs, often without significant neurological involvement, and many individuals survive into adulthood. An intermediate phenotype exists between the two extremes.
Because Type A and Type B share the same underlying enzyme deficiency but differ substantially in severity and neurological involvement, accurate clinical and genetic characterization is essential for prognosis discussions and treatment planning.
Types and Clinical Subtypes
Niemann-Pick Disease Type A/B is classified along a clinical spectrum based on severity and neurological involvement.
Symptoms and Signs
Symptoms vary widely based on whether the presentation is closer to Type A or Type B on the disease spectrum.
Causes and Risk Factors
Niemann-Pick Disease Type A/B is caused entirely by inherited genetic mutations and is not related to lifestyle or environmental factors.
Diagnosis and Investigations
Diagnosis combines clinical findings, enzyme testing, and genetic confirmation.
Disease Severity Stratification
Niemann-Pick Disease Type A/B does not use a tumor-style staging system; severity is classified along the Type A to Type B clinical spectrum.
Standard Treatment Options
Management differs significantly between Type A and Type B, with enzyme replacement therapy available for non-neurological (Type B) disease.
Advanced and Emerging Treatment Options
Enzyme replacement therapy has changed management for non-neurological disease, while research continues into approaches that could address neurological involvement.
Enzyme Replacement Therapy
Recombinant acid sphingomyelinase (olipudase alfa)
Approved enzyme replacement therapy for non-neurological manifestations of ASM deficiency, reducing organomegaly and improving lung and blood parameters.
Gene Therapy
Investigational gene therapy approaches
Early research is exploring gene-based strategies that could potentially address both visceral and neurological disease.
Cellular Therapy
Hematopoietic stem cell transplant (selected cases)
Has been explored in limited cases, though enzyme replacement therapy is now generally preferred for non-neurological disease.
Biomarkers and Molecular Testing
Biochemical and genetic markers support diagnosis, phenotype prediction, and monitoring of treatment response.
When a Second Opinion May Be Important
Because the clinical spectrum between Type A and Type B is broad, specialist review can help clarify phenotype and treatment eligibility.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Prognosis differs substantially between Type A and Type B. Type B disease, especially with access to enzyme replacement therapy, is associated with a markedly better long-term outlook than Type A.
Supportive Care and Living with Niemann-Pick Disease Type A/B
Supportive care addresses organ-specific complications and quality of life across the disease spectrum.
How CancerFax Helps You Explore Treatment Options
CancerFax can help families with Niemann-Pick Disease Type A/B obtain specialist medical report review, coordinate second opinions, and connect with centers experienced in enzyme replacement therapy and comprehensive care for ASM deficiency.
Get a free case reviewFrequently Asked Questions
Niemann-Pick Disease Type A and Type B are inherited lysosomal storage disorders caused by deficiency of acid sphingomyelinase, leading to accumulation of sphingomyelin in the liver, spleen, lungs, and in Type A, the brain.
Type A is a severe, rapidly progressive infantile form with significant neurological involvement, while Type B primarily affects the liver, spleen, and lungs with little to no neurological impact and a generally milder course.
It is caused by mutations in the SMPD1 gene, inherited in an autosomal recessive pattern.
Early signs often include an enlarged liver and spleen, poor growth, and in Type A, progressive loss of developmental milestones in infancy.
Diagnosis involves measuring acid sphingomyelinase enzyme activity and confirming the diagnosis with SMPD1 genetic testing.
Yes, an enzyme replacement therapy is approved for non-neurological manifestations of ASM deficiency and can reduce organ enlargement and improve lung and blood parameters.
Currently, there is no approved disease-modifying therapy for the neurological manifestations of Type A; care focuses on supportive and palliative management, while research into CNS-targeted approaches continues.
Care typically involves medical geneticists, hepatologists, pulmonologists, hematologists, and neurologists depending on the disease phenotype.
Yes. Because the condition is autosomal recessive, genetic counseling helps families understand recurrence risk and testing options for future pregnancies.
Yes. CancerFax can help families review medical reports, coordinate second opinions with specialists experienced in ASM deficiency, and connect with centers offering enzyme replacement therapy, including cross-border coordination where needed.
Get Expert Guidance for Niemann-Pick Disease Type A/B
Connect with specialists experienced in ASM deficiency to review your medical reports and discuss treatment options.